Ferraro, M.G.; Bocchetti, M.; Riccardi, C.; Trifuoggi, M.; Paduano, L.; Montesarchio, D.; Misso, G.; Santamaria, R.; Piccolo, M.; Irace, C.
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem. Int. J. Mol. Sci. 2023, 24, 6473.
https://doi.org/10.3390/ijms24076473
AMA Style
Ferraro MG, Bocchetti M, Riccardi C, Trifuoggi M, Paduano L, Montesarchio D, Misso G, Santamaria R, Piccolo M, Irace C.
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem. International Journal of Molecular Sciences. 2023; 24(7):6473.
https://doi.org/10.3390/ijms24076473
Chicago/Turabian Style
Ferraro, Maria Grazia, Marco Bocchetti, Claudia Riccardi, Marco Trifuoggi, Luigi Paduano, Daniela Montesarchio, Gabriella Misso, Rita Santamaria, Marialuisa Piccolo, and Carlo Irace.
2023. "Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem" International Journal of Molecular Sciences 24, no. 7: 6473.
https://doi.org/10.3390/ijms24076473
APA Style
Ferraro, M. G., Bocchetti, M., Riccardi, C., Trifuoggi, M., Paduano, L., Montesarchio, D., Misso, G., Santamaria, R., Piccolo, M., & Irace, C.
(2023). Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem. International Journal of Molecular Sciences, 24(7), 6473.
https://doi.org/10.3390/ijms24076473